Source-grounded facts extracted from BioXcel Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BioXcel Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $206,000, net income net loss of $12.7 million.
“FDA approval in an adjacent indication, which is further reinforcing the need in this therapeutic area. First Quarter 2026 Financial Results Net revenue from IGALMI® was $206,000 for the first quarter of 2026, compared to $168,000 for the same period in 2025. The Company is focused on preparing for IGALMI’s launch in the at-home setting and maintaining”
BioXcel Therapeutics, Inc. issued 1,353,729 shares of common stock of warrant to the lenders under the Ninth Amendment for exercise price of $0.01 per share.
“On April 15, 2026, the Company granted the lenders under the Ninth Amendment (the "Lenders") warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share (the "Amendment Warrants").”
BioXcel Therapeutics, Inc. reported financial results for for the three months and year ended December 31, 2025.
“On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update.”
BioXcel Therapeutics, Inc. amended Warrant Amendment Agreement with the Purchaser valued at approximately $173,135 (effective 2026-03-10).
“In connection with the Offering, pursuant to the terms of a Warrant Amendment Agreement, dated as of March 10, 2026 (the “Warrant Amendment Agreement”), the exercise price of certain outstanding warrants issued on March 27, 2024 and November 25, 2024 to purchase up to an aggregate of 1,385,083 shares of Common Stock held by the Purchaser was reduced to $1.614 per share”
BioXcel Therapeutics, Inc. entered into Purchase Agreement with the Purchaser valued at approximately $7.8 million (effective 2026-03-10).
“On March 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein”
BioXcel Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company’s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to make timely request for a hearing before the Panel to appeal the Staff’s determination. The Company’s request for a hearing will stay any further action by the Staff pending the ultimate outcome of the hearing. The Company’s common sto”
BioXcel Therapeutics, Inc.: Approved a 1-for-16 reverse stock split of common stock via amendment to the Amended and Restated Certificate of Incorporation (effective 2025-02-07).
“On February 6, 2025, BioXcel Therapeutics, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).”
Dr. Rajiv Patni was appointed as Director at BioXcel Therapeutics, Inc..
“On January 15, 2025, the Board appointed Dr. Rajiv Patni to the Board, effective January 15, 2025.”
David Mack was appointed as Director at BioXcel Therapeutics, Inc..
“On November 21, 2024, the Board appointed David Mack to the Board, effective as of November 21, 2024.”
Matthew Wiley departed as Senior Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..
“Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “ Company ”), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024”
BioXcel Therapeutics, Inc. announced a restructuring with charges of approximately $1.4 million (15 employees, or approximately 28% of the Company’s headcount).
“On September 17, 2024, the Board of Directors (the “Board”) of BioXcel Therapeutics, Inc. (the “Company”) approved a plan to reduce its workforce by 15 employees, or approximately 28% of the Company’s headcount (the “Clinical Prioritization”), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. The Company estimates that it will incur aggregate charges in connection with the Clinical Prioritization of approximately $1.4 million”
Matt Wiley departed as Chief Commercial Officer at BioXcel Therapeutics, Inc..
“On September 18, 2024, the Company notified Matt Wiley, the Company’s Chief Commercial Officer, that, in connection with the Clinical Prioritization, his position was being eliminated.”
BioXcel Therapeutics, Inc. reported first quarter of 2024 results: revenue $582,000, net income $26.8 million.
“of BXCL701 and KEYTRUDA® (pembrolizumab) in metastatic pancreatic ductal adenocarcinoma (PDAC). First Quarter 2024 Financial Results Net Revenue: Net revenue from IGALMI was $582,000 for the first quarter of 2024, compared to $206,000 for the same period in 2023, representing a 182% increase. Sequential quarterly revenue increased 55% in Q1 2024 from the”
BioXcel Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein (collectively, the "Purchasers") valued at approximately $24.9 million (effective 2024-03-25).
“On March 25, 2024, BioXcel Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (collectively, the “Purchasers”).”
BioXcel Therapeutics, Inc. reported the fourth quarter and full year 2023 results: revenue Net revenue from IGALMI was $376,000 for the fourth quarter of 2023.
“Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.”
BioXcel Therapeutics, Inc. amended Third Amendment to Credit Agreement and Guaranty with Oaktree Fund Administration LLC, as administrative agent, and the lenders (effective 2024-02-12).
“On February 12, 2024, BioXcel Therapeutics, Inc. (the “Company”) entered into the Third Amendment to Credit Agreement and Guaranty (the “Third Amendment”), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the “Lenders”), and Oaktree Fund Administration LLC (“OFA”) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, and the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the “Existing Credit Agreement”).”
BioXcel Therapeutics, Inc. amended term loan of The $30,000,000 in financing previously provided to the Company under the RIFA was converted to an outstanding loan unde with Lenders.
“Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865,000 at any time outstanding in OnkosXcel Therapeutics, LLC (“OnkosXcel”), increased from $30,000,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or”
BioXcel Therapeutics, Inc. terminated Revenue Interest Financing Agreement with the purchasers party thereto and Oaktree Fund Administration LLC (effective 2023-12-05).
“the Company terminated the Revenue Interest Financing Agreement (as amended from time to time, the “RIFA”) by and among the Company, the purchasers party thereto (the “Purchasers”) and OFA, as administrative agent”
BioXcel Therapeutics, Inc. amended Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement with Oaktree Fund Administration LLC and lenders valued at up to a maximum of $30,865,000 at any time outstanding (effective 2023-12-05).
“BioXcel Therapeutics, Inc. (the “Company”) entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the “Second Amendment”), which amended the Credit Agreement and Guaranty”
BioXcel Therapeutics, Inc. reported third quarter ended Sept. 30, 2023 results: revenue approximately $341,000, net income $50.5 million.
“OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A. 2 Third Quarter 2023 Financial Results Net Revenue: Net revenue of IGALMI was approximately $341,000 for the quarter. Research and Development (R&D) Expenses: R&D expenses were $19.6 million for the third quarter of 2023, compared to $22.1 million for the same period in 2022. The”
Krishnan Nandabalan resigned as Director at BioXcel Therapeutics, Inc..
“On September 19, 2023, Dr. Nandabalan resigned as a member of the Company’s Board of Directors”
BioXcel Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 14, 2023, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023 and provided a business update.”
BioXcel Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-26 meeting.
“Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,849,840 51,173 7,597 0”
BioXcel Therapeutics, Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders in 2026 and until his successor has been duly elected and qualified. at the 2023-06-26 meeting.
“NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Sandeep Laumas, M.D. 12,360,360 8,899,824 3,648,426 Michael Miller 21,149,269 110,915 3,648,426 Michal Votruba, M.D. 18,041,794 3,218,390 3,648,426”
BioXcel Therapeutics, Inc. reported financial results for three months ended March 31, 2023.
“On May 8, 2023, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023 and provided a business update.”
BioXcel Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
“BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on key strategic initiatives.”
William P. Kane, Jr. resigned as Executive Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..
“On October 8, 2021, William P. Kane, Jr., Executive Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “Company”) tendered his resignation notice to the Company, effective immediately.”
Reina Benabou resigned as Senior Vice President and Chief Development Officer at BioXcel Therapeutics, Inc..
“On July 19, 2021, Reina Benabou, M.D., Ph.D., Senior Vice President and Chief Development Officer of BioXcel Therapeutics, Inc. (the “Company”), and a named executive officer in the Company’s proxy statement filed April 27, 2021, tendered her resignation notice to the Company, effective July 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.